Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
0-84 |
Sentence |
denotes |
Treatment of keratosis pilaris with 810-nm diode laser: a randomized clinical trial. |
T2 |
85-96 |
Sentence |
denotes |
IMPORTANCE: |
T3 |
97-289 |
Sentence |
denotes |
Keratosis pilaris (KP) is a common skin disorder of follicular prominence and erythema that typically affects the proximal extremities, can be disfiguring, and is often resistant to treatment. |
T4 |
290-408 |
Sentence |
denotes |
Shorter-wavelength vascular lasers have been used to reduce the associated erythema but not the textural irregularity. |
T5 |
409-419 |
Sentence |
denotes |
OBJECTIVE: |
T6 |
420-599 |
Sentence |
denotes |
To determine whether the longer-wavelength 810-nm diode laser may be effective for treatment of KP, particularly the associated skin roughness/bumpiness and textural irregularity. |
T7 |
600-634 |
Sentence |
denotes |
DESIGN, SETTING, AND PARTICIPANTS: |
T8 |
635-859 |
Sentence |
denotes |
We performed a split-body, rater-blinded, parallel-group, balanced (1:1), placebo-controlled randomized clinical trial at a dermatology outpatient practice of an urban academic medical center from March 1 to October 1, 2011. |
T9 |
860-962 |
Sentence |
denotes |
We included all patients diagnosed as having KP on both arms and Fitzpatrick skin types I through III. |
T10 |
963-1038 |
Sentence |
denotes |
Of the 26 patients who underwent screening, 23 met our enrollment criteria. |
T11 |
1039-1208 |
Sentence |
denotes |
Of these, 18 patients completed the study, 3 were lost to or unavailable for follow-up, and 2 withdrew owing to inflammatory hyperpigmentation after the laser treatment. |
T12 |
1209-1223 |
Sentence |
denotes |
INTERVENTIONS: |
T13 |
1224-1301 |
Sentence |
denotes |
Patients were randomized to receive laser treatment on the right or left arm. |
T14 |
1302-1416 |
Sentence |
denotes |
Each patient received treatment with the 810-nm pulsed diode laser to the arm randomized to be the treatment site. |
T15 |
1417-1509 |
Sentence |
denotes |
Treatments were repeated twice, for a total of 3 treatment visits spaced 4 to 5 weeks apart. |
T16 |
1510-1537 |
Sentence |
denotes |
MAIN OUTCOMES AND MEASURES: |
T17 |
1538-1761 |
Sentence |
denotes |
The primary outcome measure was the difference in disease severity score, including redness and roughness/bumpiness, with each graded on a scale of 0 (least severe) to 3 (most severe), between the treated and control sites. |
T18 |
1762-1841 |
Sentence |
denotes |
Two blinded dermatologists rated the sites at 12 weeks after the initial visit. |
T19 |
1842-1850 |
Sentence |
denotes |
RESULTS: |
T20 |
1851-2009 |
Sentence |
denotes |
At follow-up, the median redness score reported by the 2 blinded raters for the treatment and control sides was 2.0 (interquartile range [IQR], 1-2; P = .11). |
T21 |
2010-2161 |
Sentence |
denotes |
The median roughness/bumpiness score was 1.0 (IQR, 1-2) for the treatment sides and 2.0 (IQR, 1-2) for the control sides, a difference of 1 (P = .004). |
T22 |
2162-2344 |
Sentence |
denotes |
The median overall score combining erythema and roughness/bumpiness was 3.0 (IQR, 2-4) for the treatment sides and 4.0 (IQR, 3-5) for the control sides, a difference of 1 (P = .005). |
T23 |
2345-2371 |
Sentence |
denotes |
CONCLUSIONS AND RELEVANCE: |
T24 |
2372-2589 |
Sentence |
denotes |
Three treatments with the 810-nm diode laser may induce significant improvements in skin texture and roughness/bumpiness in KP patients with Fitzpatrick skin types I through III, but baseline erythema is not improved. |
T25 |
2590-2742 |
Sentence |
denotes |
Complete treatment of erythema and texture in KP may require diode laser treatment combined with other laser or medical modalities that address redness. |
T26 |
2743-2806 |
Sentence |
denotes |
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01281644. |
T1 |
0-84 |
Sentence |
denotes |
Treatment of keratosis pilaris with 810-nm diode laser: a randomized clinical trial. |
T2 |
85-96 |
Sentence |
denotes |
IMPORTANCE: |
T3 |
97-289 |
Sentence |
denotes |
Keratosis pilaris (KP) is a common skin disorder of follicular prominence and erythema that typically affects the proximal extremities, can be disfiguring, and is often resistant to treatment. |
T4 |
290-408 |
Sentence |
denotes |
Shorter-wavelength vascular lasers have been used to reduce the associated erythema but not the textural irregularity. |
T5 |
409-419 |
Sentence |
denotes |
OBJECTIVE: |
T6 |
420-599 |
Sentence |
denotes |
To determine whether the longer-wavelength 810-nm diode laser may be effective for treatment of KP, particularly the associated skin roughness/bumpiness and textural irregularity. |
T7 |
600-634 |
Sentence |
denotes |
DESIGN, SETTING, AND PARTICIPANTS: |
T8 |
635-859 |
Sentence |
denotes |
We performed a split-body, rater-blinded, parallel-group, balanced (1:1), placebo-controlled randomized clinical trial at a dermatology outpatient practice of an urban academic medical center from March 1 to October 1, 2011. |
T9 |
860-962 |
Sentence |
denotes |
We included all patients diagnosed as having KP on both arms and Fitzpatrick skin types I through III. |
T10 |
963-1038 |
Sentence |
denotes |
Of the 26 patients who underwent screening, 23 met our enrollment criteria. |
T11 |
1039-1208 |
Sentence |
denotes |
Of these, 18 patients completed the study, 3 were lost to or unavailable for follow-up, and 2 withdrew owing to inflammatory hyperpigmentation after the laser treatment. |
T12 |
1209-1223 |
Sentence |
denotes |
INTERVENTIONS: |
T13 |
1224-1301 |
Sentence |
denotes |
Patients were randomized to receive laser treatment on the right or left arm. |
T14 |
1302-1416 |
Sentence |
denotes |
Each patient received treatment with the 810-nm pulsed diode laser to the arm randomized to be the treatment site. |
T15 |
1417-1509 |
Sentence |
denotes |
Treatments were repeated twice, for a total of 3 treatment visits spaced 4 to 5 weeks apart. |
T16 |
1510-1537 |
Sentence |
denotes |
MAIN OUTCOMES AND MEASURES: |
T17 |
1538-1761 |
Sentence |
denotes |
The primary outcome measure was the difference in disease severity score, including redness and roughness/bumpiness, with each graded on a scale of 0 (least severe) to 3 (most severe), between the treated and control sites. |
T18 |
1762-1841 |
Sentence |
denotes |
Two blinded dermatologists rated the sites at 12 weeks after the initial visit. |
T19 |
1842-1850 |
Sentence |
denotes |
RESULTS: |
T20 |
1851-2009 |
Sentence |
denotes |
At follow-up, the median redness score reported by the 2 blinded raters for the treatment and control sides was 2.0 (interquartile range [IQR], 1-2; P = .11). |
T21 |
2010-2161 |
Sentence |
denotes |
The median roughness/bumpiness score was 1.0 (IQR, 1-2) for the treatment sides and 2.0 (IQR, 1-2) for the control sides, a difference of 1 (P = .004). |
T22 |
2162-2344 |
Sentence |
denotes |
The median overall score combining erythema and roughness/bumpiness was 3.0 (IQR, 2-4) for the treatment sides and 4.0 (IQR, 3-5) for the control sides, a difference of 1 (P = .005). |
T23 |
2345-2371 |
Sentence |
denotes |
CONCLUSIONS AND RELEVANCE: |
T24 |
2372-2589 |
Sentence |
denotes |
Three treatments with the 810-nm diode laser may induce significant improvements in skin texture and roughness/bumpiness in KP patients with Fitzpatrick skin types I through III, but baseline erythema is not improved. |
T25 |
2590-2742 |
Sentence |
denotes |
Complete treatment of erythema and texture in KP may require diode laser treatment combined with other laser or medical modalities that address redness. |
T26 |
2743-2806 |
Sentence |
denotes |
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01281644. |